MedTrace Logo

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-12-18

Study results available
· View outcomes & findings →

Summary

The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)

Conditions

Interventions

DRUG

KAN-101

Dose KAN-101 Intravenous (IV) Infusion

DRUG

Placebo

Placebo Intravenous (IV) Infusion

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

    lead INDUSTRY

Principal Investigators

  • Study Director · Anokion SA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2025-01-03
Completion
2025-01-13
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Finland
  • Germany
  • Ireland
  • Israel
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06001177 on ClinicalTrials.gov